Public Profile

Coherus BioSciences, Inc.

Coherus BioSciences, Inc., a leading biotechnology firm headquartered in the United States, focuses on the development and commercialisation of innovative biologic therapies. Founded in 2010, the company has made significant strides in the biosimilars market, particularly in oncology and autoimmune diseases. With a robust portfolio that includes products like Udenyca, Coherus stands out for its commitment to providing high-quality, cost-effective alternatives to expensive biologic treatments. The company operates primarily in North America, with a growing presence in international markets. Recognised for its scientific expertise and strategic partnerships, Coherus BioSciences has established a strong market position, contributing to the accessibility of essential therapies for patients worldwide.

DitchCarbon Score

How does Coherus BioSciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

18

Industry Average

Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

2

Industry Benchmark

Coherus BioSciences, Inc.'s score of 18 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.

84%

Coherus BioSciences, Inc.'s reported carbon emissions

Coherus BioSciences, Inc., headquartered in the US, currently does not have publicly available carbon emissions data for recent years. As such, specific figures regarding their Scope 1, 2, or 3 emissions are not provided. Additionally, there are no documented reduction targets or climate pledges outlined by the company at this time. In the context of the biopharmaceutical industry, companies are increasingly recognising the importance of sustainability and climate commitments. While Coherus BioSciences may not have disclosed specific emissions data or targets, the industry as a whole is moving towards greater transparency and accountability in addressing climate change.

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Coherus BioSciences, Inc.'s primary industry is Health and social work services (85), which is low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. Coherus BioSciences, Inc. is headquartered in US, which has a rank of low, indicating low grid carbon intensity.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Coherus BioSciences, Inc. is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
Carbon Disclosure Project
The Climate Pledge
UN Global Compact

Similar Organizations

Boehringer Ingelheim

DE
Medical, precision and optical instruments, watches and clocks (33)
Updated 3 days ago

Cullinan Therapeutics, Inc.

US
Health and social work services (85)
Updated 6 days ago

Lupin Pharmaceuticals, Inc.

US
Chemicals nec
Updated 6 days ago
DitchCarbon Score

Sandoz International GmbH

DE
Chemicals nec
Updated 6 days ago
DitchCarbon Score

Gilead Sciences

US
Research and development services (73)
Updated about 8 hours ago

Shire plc

IE
Health and social work services (85)
Updated 6 days ago
DitchCarbon Score

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers